Halozyme Therapeutics | HALO - 营业利润



金融业
股票价格
USD
资产
USD 2.67B
现金及等价物
USD 309.75M
销售成本
USD 108.75M
流动资产
USD 1B
流动负债
USD 363.21M
债务
USD 2.14B
EBIT
USD -61.77M
EBITDA
USD 219.57M
员工
350
EPS每股收益
USD 1.6
股本和储备
USD 219.64M
销售毛利
USD 297.47M
债务利息支出
USD 5.51M
贷款资金
USD 1.94B
市值
USD 10.1B
净收入
USD 150.05M
营业费用
USD 192.19M
营业利润
USD -61.77M
普通股股本
USD 118.52M
PE价格收益
11.35
税前利润
USD 180.33M
销售收入
USD 377M
销售和管理费用
USD 46.29M
股票
USD 155.47M
贸易债权人
USD 14.1M
应收帐款人
USD 457.99M


营业利润 更改 日
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Amarin USD -2.26M 564K 2025-12
Amgen USD 3.83B 130M 2026-03
Baxter International USD 66M 280.2M 2026-03
Cara Therapeutics USD -5.94M 3.55M 2025-09
Cytokinetics USD -181.23M 2.86M 2026-03
DBV Technologies USD -47.9M 2.85M 2026-03
Eli Lilly USD 9.78B 792M 2026-03
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Halozyme Therapeutics USD -61.77M 26.64M 2026-03
Intrexon USD -60.84M 26.62M 2024-06
Ionis Pharmaceuticals USD -118M 97M 2026-03
MannKind USD -76.99M 7.75M 2026-03
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Pfizer USD 4.99B 340M 2026-03
Rigel Pharmaceuticals USD 14.06M 13.61M 2024-09
United Therapeutics USD 325.8M 340.4M 2026-03
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12